CXCL13 levels were significantly higher in NMOSD (median level of 340.9 pg/mL) compared with NIND (16.1 pg/mL), OIND (14.6 pg/mL) and MS (58.4 pg/mL) (figure 3B), and trended higher in MS cases compared with NIND (not significant). This evidence concerns the gene CXCL13 and myeloid sarcoma.